RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing
RareCyte® expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit.
RareCyte® launches prostate cancer ARv7 CTC Kit for liquid biopsy analysis.
RarePlex CTC Developer Staining Kit enables custom CTC assay development by providing the ability to add up to two biomarkers-of-interest to the CTC base detection assay.
RareCyte Pharma Programs support pharma development through our expert product development teams. Our services span the range from RUO product development for pre-clinical and clinical research to IVD support for companion diagnostic co-development.